Infinity Pharmaceuticals price target raised to $55 from $38 at RBC Capital RBC Capital expects Infiinity's stock to be pushed higher by favorable data at ASCO/ASH. The firm thinks the stock's valuation is attractive, and it maintains an Outperform rating on the shares.
News For INFI From The Last 14 Days
Check below for free stories on INFI the last two weeks.
Infinity Pharmaceuticals December volatility elevated into data at ASH 2013 Infinity Pharmaceuticals December call option implied volatility is at 102, January is at 94, April is at 81; compared to its 26-week average of 89 according to Track Data, suggesting large near term price movement into IPI-145 data being presented at the ASH 2013 Annual Meeting on December 8.